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Objectives: Highly pathogenic viruses such as EBOV are a threat to routine laboratory workers. Inacti-
vation procedures with Triton X-100 0.1% and/or heat are currently recommended, but have unknown
effects on the accuracy of serological testing. Furthermore, virus inactivation by Triton X-100 0.1% was
shown to be ineffective in serum. This study aimed to demonstrate virus inactivation in serum by Triton
X-100 1% and maintained accuracy of serological testing.
Methods: A panel of 19 serological tests was run on patient serum samples after treatment with Triton X-
100 1%, 0.1%, and 0.1% þ heat inactivation at 60C for 1 h. Mean differences between measurements (bias)
were calculated applying the BlandeAltman method. To determine effectiveness of virus inactivation,
herpes simplex virus 1 (HSV-1) was spiked into medium containing 90% or 1% serum, and treated with
Triton X-100 0.1% or 1%. Infectious titres were then determined on Vero cells.
Results: Serological measurements showed good agreement between controls and samples treated with
Triton X-100 0.1% and 1%, with an estimated bias of 0.6 ± 9.2% (n ¼ 258) and e0.1 ± 18.6% (n ¼ 174),
respectively. Discordant qualitative results were rare. Conversely, heat inactivation alone and combined
with Triton X-100 0.1% triggered a bias of 17.5 ± 66.4% (n ¼ 200) and 37.9 ± 79.8% (n ¼ 160), respectively.
Triton X-100 1% completely inactivated HSV-1 in 1% and 90% serum while Triton X-100 0.1% failed to do
so in 90% serum.
Conclusions: Unlike heat inactivation, Triton X-100 1% enabled accurate serological testing and
completely inactivated HSV-1 in serum. This simple method could allow safe routine serological di-
agnostics in high-risk patients. M.M. Remy, Clin Microbiol Infect 2018;▪:1
© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Highly pathogenic viruses such as EBOV or SARS coronavirus are
a continuous threat to clinical laboratory workers. The current
epidemic of Lassa virus in Nigeria is one of the latest concerns [1]
and European hospitals must be prepared to deal with potentially
infected returning travellers. While themicrobiological diagnosis of
such viruses should be performed under the required biosafety
measures in specialized laboratories, blood samples from patients
arriving at the emergency rooms are often sent directly to the
routine laboratory where biosafety levels are low.ute for Infectious Diseases,
itzerland.
Remy).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).
et al., Effective chemical virus
ction (2018), https://doi.org/1Early symptoms caused by highly pathogenic viruses are usually
non-speciﬁc and require differential diagnosis of other infectious
diseases such as malaria, Dengue fever, HIV, HBV, or CMV in-
fections. In conﬁrmed cases, a potentially long stay in intensive care
increases risks of secondary infections such as invasive fungal in-
fections. Diagnosis of these pathologies remains mostly based on
serology. Polymerase chain reaction (PCR) is an alternative diag-
nostic method that can be safely performed on infectious samples
[2,3]; however, it is only appropriate during the viraemic phase.
To inactivate highly pathogenic viruses in serum the World
Health Organization (WHO) and the US Center for Diseases Control
and Prevention (CDC) recommend chemical inactivation with
Triton X-100 0.1%, heat inactivation at 56C for 30 min, or a com-
bination thereof [4,5]. Triton X-100 is a non-ionic surfactant which
can disrupt the lipid membrane of enveloped viruses without
affecting proteins. It is therefore widely used in combination withof Clinical Microbiology and Infectious Diseases. This is an open access article under
inactivation of patient serum compatiblewith accurate serodiagnosis
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procedures of plasma products for transfusion [6]. Besides, Triton
X-100 0.1% has been successfully evaluated for haematology and
clinical chemistry [7e10] and for malaria rapid diagnostic tests
(RDTs) [11,12]. Accuracy of immunoassays after Triton X-100
treatment of serum was only partially assessed in 1988 and no
decrease in sensitivity was reported [13].
Heat inactivation was compatible with detection of EBOV-spe-
ciﬁc IgG and IgM [14] and other viral antigens [15]. However clinical
chemistry studies showed that protein measurements and espe-
cially enzymatic activity measurements were mildly to severely
affected by heat [8,16e18]. Other easily applicable inactivation
methods such as SDS treatment unfortunately denature proteins
and are not suited for serological or clinical chemistry tests [10,19].
Efﬁcacy of heat inactivation was demonstrated for several
enveloped viruses [20,21], including haemorrhagic fever viruses
[18]. Concerning detergents, complete inactivation of HIV was
achieved with 0.2% of Triton X-100 [13] whereas EBOV treatment
with 0.1% of Triton X-100 led to incomplete inactivationwith a 4 log
infectivity reduction [22]. Besides, it has been recently claimed that
the inactivation potential of Triton X-100 0.1% was annulled in
serum [10]. Inactivation tests were indeed performed on EBOV and
herpes simplex virus type 1 (HSV-1) in 0.98%, 9.8%, or 98% serum,
and viral inactivation by Triton X-100 only succeeded in medium
with less than 10% serum, suggesting that some factors in serum
interfere with detergent effects. In practice, Triton X-100 concen-
tration is often increased to 1% to ensure a higher level of safety
although no inactivation data support this choice. It thus remains to
be determined if a higher concentration of Triton X-100 can over-
come efﬁciency issues in serum.
The objective of our study was to assess the accuracy of a wide
range of serological tests after chemical or thermal inactivation of
serum. Triton X-100 0.1% or 1% ﬁnal concentration and/or heat
inactivation at 60C for 60 min were selected as promising inactiva-
tion methods. In addition, HSV-1 inactivation tests were performed
with Triton X-100 0.1% and 1% in medium containing 1% or 90%
serum. We hypothesize that a tenfold increase of Triton X-100 ﬁnal
concentration might allow complete virus inactivation in serum.
Methods
Ethics and sample selection
All human blood samples were obtained for routine patient sero-
logical testing at the Institute for Infectious Diseases, University of
Bern, Switzerland. There was no suspicion of highly pathogenic virus
infection in these patients. Sera used in this study were stored at
e20C for less than5 years. Theywere retrospectively identiﬁedusing
the electronic database of the Institute for Infectious Diseases of the
University of Bern according to the serological tests originally per-
formed and to the results obtained. Each selected serum sample was
anonymized and tested for the same serological test as originally.
Informed consent for use of anonymized leftover patientmaterialwas
waived. This procedure has been approved by the Cantonal Research
Ethics Committee of Bern, Switzerland (BASEC-No Req-2018-00288).
Serum inactivation for serological testing
The chemical inactivation procedure consisted of mixing patient
serum 10:1 with PBS or Triton X-100 1% or 10% working solution
(please see Supplementary Materials). Samples were incubated for
60 min at room temperature. Final concentrations of Triton X-100
were 0.1% and 1% (precisely 0.09% and 0.9%). Some of the samples
treated with PBS or Triton X-100 1% were additionally thermally
inactivated by incubation at 60C for 1 h in a table top thermoblockPlease cite this article in press as: RemyMM, et al., Effective chemical virus
of infections, Clinical Microbiology and Infection (2018), https://doi.org/1without shaking. Samples were then kept amaximumof 24 h at 4C
before being used for different serological tests.
Serological tests
Pre-treated samples were analysed in parallel with the
following methods. HIV, HCV, HBV, EBV, CMV, and toxoplasmosis
markers (Ag, total Ig, IgM and/or IgG) were analysed on an Archi-
tect® system (Abbott Diagnostics), a fully automated immuno-
analyser based on chemiluminescent microparticle immunoas-
says (CMIAs). Antibodies to Brucella species (IgM and IgG) were
tested by indirect chemiluminescent immunoassay (CLIA) on
another fully automated analyser (VirClia®, VirCell, Granada,
Spain). For aspergillosis, a galactomanan test (PLATELIA™ ASPER-
GILLUS Ag, Biorad 62794, Hercules, CA, USA) was performed
manually. Antibodies to Dengue virus (IgM, IgG) were detected by a
manual ELISA (Euroimmun EI 266b-9601).
Reactivity to Francisella tularensis was evaluated by a rapid test
(Virapid Tularemia, Viracell Microbiologists VR006) and by a
microagglutination test using F. tularensis Ag (Becton Dickinson
241050, Franklin Lakes, NJ, USA). All manual tests were performed
according to the manufacturer's instructions.
Please see Supplementary Materials for further details.
HSV-1 inactivation and titration
Concentrated HSV-1 stockwas spiked inMEM containing 1% FBS
or in pure human serum from an HSV-1 seronegative donor. It was
then mixed 10:1 with Triton X-100 working solution and incubated
for 1 h at room temperature. Final concentrations of Triton X-100
were 0.1% and 1% (precisely 0.09% and 0.9%). Final concentrations of
serum were 90% for human serum and 1% for FBS. Initial viral titre
in these samples ranged between 1.4  107 and 7.6  107 TCID50/
mL. Excess detergent was removed from inactivated viral samples
(please see Supplementary Materials) and each sample was then
titrated on Vero cells (please see Supplementary Materials). Each
experiment was repeated twice. Controls containing Triton X-100
without virus were also ﬁltered and titrated to evaluate cytotoxicity
caused by residual detergent.
Statistics
Graphpad Prism (version 7.04) was used to plot and analyse
data. For serological test results, BlandeAltman plots were con-
structed to evaluate differences between treated and untreated
samples as percentage of differences from the mean (bias). Sero-
logical results from chemically inactivated samples were addi-
tionally analysed by the Deming linear regression model.
Spearman's correlation coefﬁcients were calculated (data did not
pass the D'Agostino and Pearson normality test). To assess agree-
ment of qualitative items Cohen's weighted kappa coefﬁcients were
calculated with GraphPad QuickCalcs.
HSV-1 titres were log-converted to obtain a near-normal distri-
bution for statistical analysis. One-wayanalysis of variance (ANOVA)
was performed followed byDunnett's post test to comparemultiple
groups to a control group. A p value >0.05 was considered not sig-
niﬁcant (ns); p < 0.001 was considered highly signiﬁcant (***).
Results
Serological test results of chemically or thermally inactivated
patient serum samples
Patient serum samples received for routine serological testing
were chemically inactivated with Triton X-100 at a ﬁnalinactivation of patient serum compatiblewith accurate serodiagnosis
0.1016/j.cmi.2018.10.016
Table 1
Accuracy of ELISA-based serological tests after chemical and/or thermal inactivation of serum
Baseline values Triton X-100 0.1% Triton X-100 1% Heat Triton X-100 0.1% + heat
n % Bias ± SD 95% LoA FRR, %
(95% CI)
n % Bias ± SD 95% LoA FRR, %
(95% CI)
n % Bias ± SD 95% LoA FRR, %
(95% CI)
n % Bias ± SD 95% LoA FRR, %
(95% CI)
CMIA 201 e0.9 ± 9.4 e19.4; 17.6 0
(0e1.9)
117 e2.7 ± 20.8 e43.4; 38.1 0.9
(0e4.7)
200 17.5 ± 66.4 e112.6; 147.5 14.5
(10.3e20)
160 37.9 ± 79.8 e118.4; 194.2 25.6
(19.5e32.9)
HIV Ag + Ab 0.2e837.9 S/CO 17 0.3 ± 1.6 e2.9; 3.5 0
(0e18.4)
10 4.2 ± 6 e7.4; 15.9 0
(0e27.8)
17 e8.2 ± 34.8 e76.5; 60 5.9
(0.3e27)
10 e15.2 ± 44 e101.4; 70.9 10
(0.5e40.4)
HCV IgG 0.2e14.1 S/CO 17 e2.2 ± 7.5 e16.9; 12.4 0
(0e18.4)
10 e1.2 ± 4.3 e9.7; 7.2 0
(0e27.8)
17 41 ± 62 e80.6; 162.6 11.8
(2.1e34.3)
11 84.8 ± 61.2 e35.1; 204.8 63.6
(35.4e84.8)
HBV HBs Ag 0.22e5410.5 S/CO 22 e7.6 ± 10.2 e27.5; 12.3 0
(0e14.9)
10 e14.5 ± 34.4 e81.9; 53 0
(0e27.8)
22 10 ± 20.1 e29.4; 49.4 0
(0e14.9)
15 12.4 ± 26.3 e39.1; 63.9 0
(0e20.4)
HBV HBs IgG 0.5e900 mIU/mL 22 2.9 ± 8.9 e14.6; 20.3 0
(0e14.9)
10 e11.6 ± 32.2 e74.7; 51.6 0
(0e27.8)
21 e12.2 ± 24.7 e60.7; 36.2 4.8
(0.2e22.7)
8 e16.9 ± 43.7 e102.6; 68.8 0
(0e32.4)
HBV HBc Ig 0.2e10.1 S/CO 22 e1.1 ± 6.3 e13.4; 11.3 0
(0e14.9)
10 e16.8 ± 43.9 e102.7; 69.2 10
(0.5e40.4)
22 24.9 ± 47.6 e68.4; 118.1 9.1
(1.6e27.8)
15 66.8 ± 59.7 e50.2; 183.7 26.7
(10.9e52)
EBV VCA IgM 0.2e19.2 S/CO 15 0.2 ± 3.3 e6.2; 6.6 0
(0e20.4)
9 2.5 ± 4.2 e5.7; 10.7 0
(0e29.9)
15 e35.7 ± 37.8 e109.8; 38.4 0
(0e20.4)
15 e37.5 ± 47.9 e131.4; 56.5 0
(0e20.4)
EBV VCA IgG 0.2e68.8 S/CO 15 2.3 ± 16.5 e30; 34.7 0
(0e20.4)
9 e2.7 ± 3.4 e9.2; 3.9 0
(0e29.9)
15 69 ± 83.3 e94.4; 232.3 13.3
(2.4e37.9)
15 84 ± 78.3 e69.4; 237.5 13.3
(2.4e37.9)
EBV EBNA IgG 0.2e21.2 S/CO 15 1.4 ± 3.9 e6.3; 9.1 0
(0e20.4)
9 e1.9 ± 4.4 e10.6; 6.8 0
(0e29.9)
15 50.3 ± 55.2 e57.9; 158.6 40
(19.8e64.3)
15 72.1 ± 66.6 e58.4; 202.5 60
(35.7e80.2)
CMV IgM 0.2e8.7 S/CO 14 1.6 ± 4.9 e8; 11.2 0
(0e21.5)
10 4 ± 7.6 e10.9; 18.9 0
(0e27.8)
14 e0.8 ± 80.8 e159.1; 157.5 21.4
(7.6e47.6)
14 60.1 ± 72.5 e81.9; 202.2 21.4
(7.6e47.6)
CMV IgG 0.27e225 AU/mL 14 e2.8 ± 19.4 e40.8; 35.2 0
(0e21.5)
10 11.8 ± 17.3 e22; 45.6 0
(0e27.8)
14 95.2 ± 92.9 e86.8; 277.2 50
(26.8e73.2)
14 109.3 ± 95.2 e77.3; 295.9 57.1
(32.6e78.6)
Toxo IgM 0.2e19.1 S/CO 14 e1.6 ± 4.5 e10.4; 7.3 0
(0e21.5)
10 e1.8 ± 6.8 e15.1; 11.6 0
(0e27.8)
14 e44.6 ± 33.3 e109.7; 20.6 21.4
(7.6e47.6)
14 e49.1 ± 36.5 e120.6; 22.5 21.4
(7.6e47.6)
Toxo IgG 0.2e180 IU/mL 14 e2.8 ± 7.7 e17.9; 12.3 0
(0e21.5)
10 e3.6 ± 9.8 e22.8; 15.5 0
(0e27.8)
14 33.7 ± 72.8 e109.1; 176.4 14.3
(2.5e39.9)
14 54.4 ± 77.8 e98.1; 207 28.6
(11.7e54.6)
CLIA 26 1.3 ± 7.7 e13.7; 16.4 0
(0e12.9)
26 3.4 ± 11.2 e18.4; 25.3 0
(0e12.9)
Brucella IgM 0.2e5.3 index 13 2.4 ± 5.6 e8.4; 13.3 0
(0e22.8)
13 5.5 ± 9.7 e13.5; 24.6 0
(0e22.8)
Brucella IgG 0.2e10 index 13 0.2 ± 9.5 e18.4; 18.7 0
(0e22.8)
13 1.3 ± 12.5 e23.1; 25.7 0
(0e22.8)
Manual ELISA 31 0.1 ± 8.7 e16.9; 17 3.2
(0.2e16.2)
31 6.4 ± 12.2 e17.6; 30.3 6.5
(1.1e20.7)
Aspergillus 0.1e7.9 index 11 e1.5 ± 12.7 e26.4; 23.5 0
(0e25.9)
11 5.9 ± 18 e29.5; 41.2 9.1
(0.5e37.7)
DENV IgM 0.1e6.4 index 10 2 ± 6.7 e11.2; 15.1 0
(0e27.8)
10 10 ± 8.8 e7.2; 27.4 0
(0e27.8)
DENV IgG 0.1e3.9 index 10 e0.2 ± 4.2 e8.5; 8.1 10
(0.5e40.4)
10 3.2 ± 5.7 e8; 14.3 10
(0.5e40.4)
Total 258 e0.6 ± 9.2 e18.6; 17.4 0.4
(0e2.2)
174 e0.1 ± 18.6 e36.7; 36.4 1.7
(0.5e4.9)
200 17.5 ± 66.4 e112.6; 147.5 14.5
(10.3e20)
160 37.9 ± 79.8 e118.4; 194.2 25.6
(19.5e32.9)
Bias, mean difference (Treated e Control) vs. average in %; LoA, BlandeAltman limits of agreement (mean ± 1.96SD); SD, standard deviation; CI, conﬁdence interval; FRR, false results rate or percentage at which the qualitative
results of the treated samples differed from that of the controls; CMIA, chemiluminescent microparticle immunoassays (Architect®, Abbott Diagnostics); CLIA, chemiluminescent immunoassay (VirClia®, VirCell); S/CO, signal-to-
cutoff ratio; HIV, human immunodeﬁciency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; EBV, EpsteineBarr virus; CMV, human cytomegalovirus; Toxo, Toxoplasma gondii; DENV, Dengue virus; Ag, antigen; Ab, antibody.














































M.M. Remy et al. / Clinical Microbiology and Infection xxx (2018) 1e64concentration of 0.1% or 1% and compared with PBS-treated con-
trols by several ELISA-based serological assays (Table 1). Samples
were carefully selected to cover a wide range of concentrations.
Qualitative results were assessed for each sample and a false result
rate (FRR) was calculated by computing false-negative and false-
positive results compared with controls for each test.
The bias of test results compared with controls (mean differ-
ences versus average) was e0.6 ± 9.2% after treatment with 0.1% of
Triton X-100 and e0.1 ± 18.6% after treatment with 1% of Triton X-
100 (Table 1, Figs. 1a,b). This good agreement was conﬁrmed by
other statistical methods including Deming linear regression with
Spearman correlation coefﬁcient >0.99 (Table S1). Automated
chemiluminescent assays (CMIA and CLIA) gave similar results to
manually performed ELISAs. Only one discordant qualitative result
was observed for Dengue IgG after treatment with Triton X-100
0.1% and concerned a sample which was around the borderline cut-
off (Table S2). The overall false result rate after treatment with 0.1%
of Triton X-100 was 0.4% (0e2.2%, Table 1). Increasing concentra-
tion of Triton X-100 to 1% led to a non-signiﬁcant increase of this
false result rate to 1.7% (0.5e4.9%, Table 1). Accordingly, serology
results were not substantially altered (Fig. 1b). False results con-
cerned the same borderline Dengue IgG sample: one sample with
an Aspergillus test value around the positive cut-off and one sample
for which HBV anti-HBc total Ig changed fromweak positive in the
control to negative in Triton X-100 1% (Table S2).
In contrast, thermal inactivation by incubation of serum samples
at 60C for 1 h yielded aberrant serological test results with a mean
bias of 17.5 ± 66.4%, which further increased to 37.9 ± 79.8% when
combined with Triton X-100 0.1% (Table 1, Figs. 1c,d). Since results




































































































Fig. 1. Agreement of serological test results after chemical or thermal inactivation of patient
control samples in percent (bias). Patient serum samples inactivated with Triton X-100 0.1% (
100 0.1% and heat inactivation (d) were used for a panel of ELISA-based serological assays
ELISAs (Man.) Control samples received an equivalent amount of PBS. Solid lines indicate m
indicate 0 (no bias). Abbreviations: HIV, human immunodeﬁciency virus; HCV, hepatitis C vir
Toxoplasma gondii; DENV, Dengue virus; Ag, antigen; Ab, antibody.
Please cite this article in press as: RemyMM, et al., Effective chemical virus
of infections, Clinical Microbiology and Infection (2018), https://doi.org/1regression analysis was performed. The most relevant changes
were seen for CMV IgG with biases of more than 95% (Table 1).
Accordingly, high false result rates were observed for most of the
assays with an average of 14.5% (10.3e20.0) after heat inactivation
and 25.6% (19.5e32.9) after the combination treatment (Table 1).
HIV antigen þ antibody (AgþAb), HBV HBs Ag, and IgG test results,
however, remained relatively unaffected by heat inactivation with
minimal bias and no discordant qualitative results (Table 1).
In addition to the ELISA-based assays, we analysed the perfor-
mances of a rapid test and a microagglutination test for the diag-
nosis of tularaemia after chemical or thermal inactivation of serum
samples (Table 2). Triton X-100 0.1% did not have an effect on the
accuracy of both tests. Triton X-100 1%, however, yielded accept-
able rapid test results but disturbed microagglutination results.
End titres were affected and several prozone and partial aggluti-
nation effects were observed. Heat inactivation yielded both poor
rapid test and poor microagglutination results with many prozone
effects.Effect of serum concentration on the chemical inactivation of HSV-1
To evaluate the inactivation potential of Triton X-100 on
enveloped viruses we chose HSV-1 as amodel virus. HSV is indeed a
prototypic enveloped virus that grows easily to high titres and for
which rapid and accurate infectivity assays are available [23]. For
these reasons it has been widely used for inactivation studies with
various detergents [10,19,24]. Since it has been recently shown that
serum annulled the inactivation effect of Triton X-100 0.1% [10] we
performed our assays in 90% human serum or in medium con-
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serum samples. BlandeAltman plots showing differences versus average of treated and
a), Triton X-100 1% (b), heat inactivation at 60C for 1 h (c), or a combination of Triton X-
including automated chemiluminescence immunoassays (CMIA and CLIA) and manual
ean bias, dashed lines indicate 95% limits of agreement (mean ± 1.96 SD), dotted lines
us; HBV, hepatitis B virus; EBV, Epstein-Barr virus; CMV, human cytomegalovirus; Toxo,
inactivation of patient serum compatiblewith accurate serodiagnosis
0.1016/j.cmi.2018.10.016
Table 2
Effect of inactivation treatments on Tularemia rapid test and microagglutination test










1 e e e e <10 <10 <10a <10
2 2þ 2þ 2þ 1þ 2560 2560 1280b 1280b
3 e e e e <10 <10 <10a <10
4 2þ 2þ 2þ 1þ 1280 1280 1280b 640b
5 2þ 2þ 1þ e 160 160 <10a <10
6 2þ 2þ 1þ ± 320 320 40a <10
7 e e e e <10 <10 80a <10
8 2þ 2þ 2þ 1þ 640 640 1280b 320b
9 2þ 2þ 2þ ± 2560 2560 1280b 1280b
10 2þ 2þ 2þ 1þ 5120 5120 10240 5120b
Weighted kappa 1.000 0.851 0.353 1.000 0.657 0.684
Bold indicates false-qualitative result.
Controls and heat-inactivated samples were treated with an equivalent volume of PBS.
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Fig. 2. Inﬂuence of serum concentration on the chemical inactivation of herpes sim-
plex virus type 1 (HSV-1). Reduction in HSV-1 titres in samples containing either 1%
fetal bovine serum (FBS) or 90% human serum after treatment with 0.1% or 1% Triton X-
100 for 1 h at room temperature. Controls received an equivalent amount of PBS.
Before titration, samples were ﬁltrated through 100-kDa membranes to remove re-
sidual Triton X-100. Unﬁltered PBS controls are shown to account for eventual virus
loss through the ﬁlter. TCID50/ml titres presented as mean ± SD were determined in
three independent experiments with 4-8 replicates per experiment. Abbreviations:
HSV-1, herpes simplex virus type 1; TCID50, 50% Tissue Culture Infectious Dose.
M.M. Remy et al. / Clinical Microbiology and Infection xxx (2018) 1e6 5As previously shown, Triton X-100 0.1% could completely inac-
tivate HSV-1 in medium containing 1% serumwith a titre reduction
of at least 5 log10 but it had no effect on HSV-1 in 90% serum (Fig. 2).
On the contrary, a Triton X-100 concentration of 1% led to complete
HSV-1 inactivation in both 1% and 90% serumwith a titre reduction
of at least 5 log10 (Fig. 2).
Discussion
Recent events including Ebola and Lassa outbreaks in West Af-
rica [1,25] and two cases of Andes Hantavirus infection in a
returning traveller at our hospital [26] drew our attention to issues
regarding biosafety for laboratory workers and optimal diagnostics
for high-risk patients. In our routine laboratory we noticed a lack of
protocols for virus inactivation and a lack of data regarding effect of
inactivation on the accuracy of serological tests.
Here we demonstrate that heat inactivation is not a suitable
method for the serological diagnosis of infectious diseases. On the
contrary routine ELISA-based-serological tests and rapid tests can
be accurately performed after a treatment with Triton X-100 0.1% or
1% ﬁnal concentration. Both quantitative and qualitative results
remained relatively unaffected and false results mostly concernedPlease cite this article in press as: RemyMM, et al., Effective chemical virus
of infections, Clinical Microbiology and Infection (2018), https://doi.org/1borderline samples. These results should prompt further studies
about the effect of Triton X-100 1% on clinical chemistry parame-
ters, haematological tests, and malaria tests for which only Triton
X-100 0.1% has been tested so far [7e12]. As recently published [10],
Triton X-100 0.1% is not sufﬁcient to inactivate HSV-1 in high
concentrations of serum. Increasing Triton X-100 ﬁnal concentra-
tion to 1% however led to complete inactivation of HSV-1 in 90%
serum samples. This is of primordial importance for the safety of
laboratory workers, considering that they receive and process un-
diluted serum samples, which are potentially infectious.
Since Triton X-100 exerts its inactivation effect at the level of the
viral envelope only, complete inactivation of HSV-1 with 1% of
Triton X-100 suggests that other enveloped viruses such as HIV,
inﬂuenza, SARS, or EBOV could also be completely inactivated by
the same procedure. This remains, however, to be tested especially
for EBOV, which is a rather stable virus [2,3]. Preliminary results of
EBOV inactivation with Triton X-100 1% for 20 min are promising
[27]. Other proven inactivationmethods such as the combination of
Triton X-100 and heat against EBOV [2,14,28] are unfortunately not
compatible with serological diagnosis and should be limited to
molecular diagnosis. Moreover, although this combination allowed
detection of EBOV-speciﬁc IgG and IgM [14], our study suggests that
inactivation procedures used for EBOV serology should be further
evaluated and compared to inactivation with Triton X-100 alone.
If proven efﬁcient for enveloped viruses in general, this simple
inactivation procedure based on a single pipetting step could be
implemented in basic microbiology laboratories and in the ﬁeld
diagnostics during outbreaks of highly pathogenic viruses where a
safe and rapid diagnosis is of primordial importance [14]. The initial
step of adding detergent to the serum sample does however require
trained personnel, rigorous safety practices, and a biosafety cabinet
of level 2. Triton X-100 has a long history of usage in diagnostic
procedures; nevertheless, it is unknown if high concentrations of
detergent could potentially affect routine laboratory analysers.
Another limitation to the broad usage of Triton X-100 consists in
environmental concerns. This reagent will soon be forbidden in
Europe because of its endocrine disruption effects in aquatic or-
ganisms [29]. Restricted usage for well-deﬁned procedures and
appropriate waste treatment solutions will most probably still be
possible in future. Ecofriendly alternatives such as lauryldimethyl-
amine N-oxide (LDAO) [30] have been shown to exhibit effective
virus inactivation in a broad range of protein concentrations but
need further evaluation with different viruses and conditions.inactivation of patient serum compatiblewith accurate serodiagnosis
0.1016/j.cmi.2018.10.016
M.M. Remy et al. / Clinical Microbiology and Infection xxx (2018) 1e66In conclusion, we showed that addition of 1% Triton X-100 to
serum samples enables complete inactivation of HSV-1 and is
compatible with accurate results of a wide range of routine sero-
logical tests. This study provides basis to the development of safe
serological assays for the rapid and accurate differential diagnosis
of infectious diseases in patients with suspected or conﬁrmed
infection with highly pathogenic viruses.
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